Circulating tumor DNA (ctDNA) allows genotyping of the tumor in multiple myeloma. Here, the authors show that minimal residual disease (MRD) by ctDNA can be detected after CAR-T therapy correlates with bone marrow-based MRD to track clonal evolution and inform treatment resistance mechanisms.
- Hitomi Hosoya
- Mia Carleton
- David M. Kurtz
